These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7194052)

  • 1. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation.
    Ritschel WA; Thompson GA; Lücker PW; Wetzelsberger K
    Arzneimittelforschung; 1980; 30(11b):2020-3. PubMed ID: 7194052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
    Lücker PW; Wetzelsberger K; Erking W; Donike M
    Arzneimittelforschung; 1980; 30(11b):2045-53. PubMed ID: 7194058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE; Kellett DN
    Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
    Ginocchio AV; Metz G
    Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of etofylline clofibrate on experimental thrombosis and platelet function.
    Sim AK; Davies ME; McCraw AP; Metz G
    Arzneimittelforschung; 1980; 30(11b):2042-5. PubMed ID: 7194057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].
    Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2014-9. PubMed ID: 7194051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On the uricosuric activity of etofylline clofibrate (author's transl)].
    Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2073-4. PubMed ID: 7194063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ; Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology and toxicology of etofylline clofibrate].
    Sterner W; Korn WD
    Arzneimittelforschung; 1980; 30(11b):2023-31. PubMed ID: 7194053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation.
    Metz G; Sim AK; McCraw AP; Cleland ME
    Arzneimittelforschung; 1986 Sep; 36(9):1363-5. PubMed ID: 3539125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
    Paltauf F; Pristautz H; el Eisch IA
    Acta Med Austriaca; 1977; 4(3):120-4. PubMed ID: 930544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioavailability of simfibrate a new clofibric acid derivative.
    Harvengt C; Desager JP
    Curr Ther Res Clin Exp; 1976 Jan; 19(1):145-151. PubMed ID: 812660
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.